Kits and containers for treating tumors expressing vimentin - Patents.com

Antibodies comprising specific heavy and light chains are used to cross the blood-brain barrier, addressing the delivery challenge and enabling effective treatment of brain tumors by maintaining potency and specificity for vimentin-expressing cancers.

JP2024544358AActive Publication Date: 2024-11-29NASCENT BIOTECH INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024524592
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-10-29
Publication Date
2024-11-29
Estimated Expiration
2041-10-29

AI Technical Summary

Technical Problem

The blood-brain barrier (BBB) poses a significant obstacle to the delivery of therapeutic agents to the brain, limiting effective treatments for brain tumors and other neurological diseases due to the inability of most biologics to cross this barrier, and existing products designed to overcome or bypass the BBB are difficult to control.

Method used

Containers containing antibodies, such as pritumumab, which comprise specific heavy and light chains (SEQ ID NO: 1 and 2), are used to cross the BBB, allowing for the delivery of therapeutic and diagnostic agents to the brain.

Benefits of technology

The antibodies effectively cross the blood-brain barrier, maintaining potency over long-term storage and enabling targeted delivery of therapeutic agents to brain tumors and other vimentin-expressing cancers, with demonstrated binding specificity and efficacy in treating these conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544358000001_ABST
    Figure 2024544358000001_ABST
Patent Text Reader

Abstract

Provided herein is a container containing a composition comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. The container can be a bottle or vial, e.g., a glass or polyethylene terephthalate G (PETG) bottle or vial. Also provided are kits comprising the container and methods of treating cancer using antibodies from the container.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] background The blood-brain barrier (BBB) ​​represents a significant barrier for the delivery of therapeutic agents to the brain. The BBB is a protective endothelial tissue that surrounds the CNS and presents a major obstacle to the systemic administration of therapeutic and diagnostic agents for the treatment of neurological diseases. For example, the treatment of brain metastases of brain tumors or other solid cancers is a highly unmet need. The lack of good treatments is due to the aggressive and infiltrative characteristics of tumors in the brain and the inability of most effective biologics to cross the BBB. If the BBB were leaky or easily traversable, new useful agents could be delivered to brain tissue. Previous products designed to overcome or circumvent the BBB have been difficult to control, limiting their usefulness. The present disclosure meets these and other needs by providing antibodies or antibody fragments that can cross the BBB. Summary of the Invention

[0002] summary Provided herein is a container containing a composition comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. The container can be a bottle or vial, e.g., a glass or polyethylene terephthalate G (PETG) bottle or vial. Also provided are kits comprising the container and methods of treating cancer using antibodies from the container. [Brief description of the drawings]

[0003] [Figure 1] FIG. 1 is a graph showing that clinical bulk antibody lots stored in PETG serum vials are more potent than clinical bulk antibody lots stored in polypropylene (PP) vials. [Diagram 2]Figure 2 is a graph showing that bulk antibody lots used as reference standards in toxicological assays have different potencies in PP and PETG vials, with the antibody stored in PETG vials being more potent than the antibody stored in PP vials. [Diagram 3] Figure 3 is a flow cytometry histogram plot showing that pritumumab binds to the cell surface of U251 glioma cells. The left peak is unstained cells and the right shifted peak is pritumumab staining. [Figure 4] 4 is a graph showing that recombinant human vimentin can compete for binding of pritumumab to glioma cells. The graph is a histogram plot showing unstained cells in the leftmost peak, pritumumab alone (160 nM) in the rightmost peak, pritumumab (160 nM) + vimentin (45 nM) in the rightmost peak overlapping with the pritumumab alone peak, and pritumumab (160 nM) + vimentin (450 nM) in the second peak from the left. [Figure 5A] Figures 5A and 5B are photographs of images from whole slide scans showing representative fields of central nervous system (CNS) neoplasms. [Figure 5B] Figures 5A and 5B are photographs of images from whole slide scans showing representative fields of central nervous system (CNS) neoplasms. [Figure 6A] 6A and 6B are photographs of images of whole slide scans showing representative fields of a normal cerebellum. [Figure 6B] 6A and 6B are photographs of images of whole slide scans showing representative fields of a normal cerebellum. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0004] Detailed Description While several example configurations have been described, various modifications, alternative constructions, and equivalents may be used without departing from the spirit of the disclosure. For example, the above elements may be components of a larger system, in which case other rules may take precedence or application of the invention may be modified. Also, many steps may be taken before, during, and after the above elements are considered.

[0005] It is to be understood that the present invention is not limited to particular methods, reagents, compounds, compositions, or biological systems. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the content clearly dictates otherwise.

[0006] As used herein, the term "about" when referring to a measurable value, such as an amount, temporal duration, and the like, is intended to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and even more preferably ±0.1% from the stated value, as such variations are appropriate for performing the disclosed methods.

[0007] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred materials and methods are described herein.

[0008] "Vertebrate," "mammal," "subject," "mammalian subject," or "patient" are used interchangeably and refer to mammals, such as human patients and non-human primates, as well as laboratory animals, such as rabbits, rats, and mice, cows, horses, goats, and other animals. Animals include all vertebrates, e.g., mammals and non-mammals, such as mice, sheep, dogs, cows, birds, ducks, geese, pigs, chickens, amphibians, and reptiles.

[0009] "Treating" or "treatment" generally refers to either (i) preventing, e.g., prophylaxis, of a disease, or (ii) reducing or eliminating, e.g., treatment, of the symptoms of the disease of interest. Thus, treatment can be prophylactic (preventing or delaying the onset of the disease, or preventing the manifestation of clinical or subclinical symptoms thereof), or therapeutically suppressing or alleviating symptoms after the manifestation of the disease.

[0010] "Prevent" or "prevention" refers to prophylactic administration with the compositions of the present invention.

[0011] A "therapeutically effective amount" or "effective amount" refers to an amount of an antibody composition sufficient to prevent a disease or to alleviate (e.g., relieve, reduce, reduce) at least one symptom associated with the disease. Administration of the composition need not completely eliminate the symptoms of the disease, so long as the benefits of administering the composition outweigh the disadvantages. Similarly, the terms "treat" and "therapeutic" as used herein with respect to a disease do not necessarily mean that the subject is cured of the disease or that all clinical signs are eliminated, but merely that some alleviation or improvement in the subject's condition is brought about by administration of the composition.

[0012] The term "cancer" as used herein refers to any type of cancer, neoplasm, or malignant tumor found in a mammal, including leukemia, carcinoma, and sarcoma. Exemplary cancers include brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, gastric cancer, uterine cancer, and medulloblastoma. Other examples include Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumor, glioblastoma, malignant insuloma, malignant carcinoid, bladder cancer, precancerous skin lesion, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, tumors of the endocrine and exocrine pancreas, and prostate cancer.

[0013] The term "antibody" as used herein refers to any immunoglobulin or intact molecule, as well as fragments thereof, that bind to a specific epitope. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab, Fab', F(ab)' fragments and / or F(v) portions of whole antibodies, and variants thereof. All isotypes are encompassed by the term, including IgA, IgD, IgE, IgG, IgM.

[0014] An intact "antibody" comprises at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain contains a heavy chain variable region (referred to herein as HCVR or V H The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain is composed of a light chain variable region (herein abbreviated as LCVR or V L The light chain constant region consists of one domain, CL. H and V LThe region can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of an antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The term antibody includes antigen-binding portions of intact antibodies that retain binding ability. Examples of binding include (i) V L , V H , C L (ii) a F(ab')2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bond at the hinge region; and (iii) a V H and an Fd fragment consisting of the CH1 domain, (iv) a V of a single arm of an antibody. L and V H (v) an Fv fragment consisting of a V domain; H domains (Ward et al., Nature, 341:544-546 (1989)), and (vi) isolated complementarity determining regions (CDRs).

[0015] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contributes to antigen binding. One of the most commonly used definitions of the six CDRs is that provided by Kabat EA et al., (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242.

[0016] As used herein, the term "single chain antibody" or "single chain Fv (scFv)" refers to a single chain antibody that is composed of two domains of an Fv fragment, V L and V H The Fv fragment is an antibody fusion molecule that consists of two domains, V L and V H are encoded by separate genes, they have been recombinantly synthesized using V L and V H The regions may be linked by synthetic linkers that allow them to be produced as a single protein chain that pairs to form a monovalent molecule (known as single-chain Fv (scFv); see, e.g., Bird et al., Science, 242:423-426 (1988); and Huston et al., Proc Natl Acad Sci USA, 85:5879-5883 (1988)). Such single chain antibodies are included by reference to the term "antibody" fragments, and may be prepared by recombinant techniques or by enzymatic or chemical cleavage of intact antibodies.

[0017] Provided herein is a container comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. Optionally, the container comprises a pharmaceutical composition comprising the antibody. Optionally, the container comprises a therapeutically effective amount of the antibody. Optionally, the container is a bottle or a vial. Optionally, the container can be made of glass or polyethylene terephthalate G (PETG). Optionally, the container is a glass vial or a PETG vial. Optionally, the container is a vial, and the vial comprises 5 mg / ml to 15 mg / ml of the antibody.

[0018] The sequences of the antibodies provided are as follows: SEQ ID NO:1: EVQLLESGGDLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSAITPSGGSTNYADSVKGRFTISRDNSQNTLYLQMNSLRVEDTAVYICGRVPYRSTWYPLYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0019] SEQ ID NO:2: DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWFQQKPGKAPKSLIYAASSLHSKVPTQFSGSGSGTDFTLTISSLQPEDFATYYCLQYSTYPITFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0020] Optionally, the antibody has an isoelectric point of 8.0 to 9.0. Optionally, the antibody has an isoelectric point of about 8.7.

[0021] Optionally, for example, in a bottle or vial, the antibody has a median effective binding concentration (EC50) of 8 to 9ug / ml. Optionally, in a glass container, the EC50 of the antibody in the glass vial is 8 to 9ug / ml. Optionally, in a PETG container, the EC50 of the antibody in the glass vial is 9 to 12ug / ml. Optionally, the EC50 value of the antibody is determined using the conditions described in the examples. In other words, the antibody may have an EC50 value of 9 to 12ug / ml under the conditions described in the examples below.

[0022] The antibody provided herein, which comprises a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2, may also be called pritumumab, and crosses the blood-brain barrier.See U.S. Patent No. 11,028,155, the entirety of which is incorporated herein by reference.Furthermore, as described in the Examples, the antibody binds to vimentin.In some cases, vimentin is located on the surface of cancer cells or secreted by cancer cells and located outside of cancer cells.In some cases, the cancer is a brain tumor.

[0023] The container containing the antibody may be stored for an extended period of time. Optionally, the period is 3, 6, 9, 12, 15, 18, 21, or 24 months or longer. Optionally, the antibody may be stored at a temperature of -60°C or lower. Optionally, the antibody maintains its activity over three freeze / thaw cycles.

[0024] As described below, the antibody may be conjugated to an agent. Optionally, the agent is a therapeutic or diagnostic agent. Optionally, the therapeutic agent is a chemotherapeutic agent. Optionally, the diagnostic agent is a fluorescent agent, a radioactive agent, or a chemiluminescent agent.

[0025] Also provided is a method of delivering an antibody across the blood-brain barrier, comprising administering to a subject an antibody described herein from a container, e.g., a bottle or vial, described herein, thereby delivering the antibody across the blood-brain barrier. Optionally, the container is a glass or PETG container.

[0026] As mentioned above, the antibodies disclosed and provided herein can be conjugated to a therapeutic moiety, such as a drug, e.g., a cytotoxin, a drug (e.g., an immunosuppressant), or a radiotoxin. Such conjugates are referred to herein as "immunoconjugates."

[0027] The antibody conjugates of the present invention may be used to modify a given biological response, and the drug moiety should not be construed as being limited to classical chemotherapeutic agents. For example, the drug moiety may be a protein or polypeptide having a desired biological activity. Such proteins include, for example, enzymatically active toxins, such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin, or active fragments thereof; proteins, such as tumor necrosis factor or interferon-γ; or biological response modifiers, such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

[0028] Pritumumab can cross the blood-brain barrier and therefore can be used as a delivery vehicle to deliver other agents, such as imaging or therapeutic agents, to the brain or other tumor tissue. Thus, a composition is provided that includes an antibody comprising a heavy chain and a light chain, the heavy chain comprising the sequence of SEQ ID NO: 1 and the light chain comprising the sequence of SEQ ID NO: 2, and one or more agents, such as imaging or therapeutic agents. Optionally, the agent is conjugated to the antibody. Optionally, the therapeutic agent is a chemotherapeutic agent. Optionally, the conjugate comprises a recombinant antigen-binding protein as described herein conjugated to one or more agents. Optionally, the composition is formulated for delivery to the brain. Optionally, the composition can cross the blood-brain barrier. Optionally, the heavy chain of the antibody comprises SEQ ID NO: 1 and the light chain comprises SEQ ID NO: 2. Optionally, the antibody is pritumumab.

[0029] Techniques for conjugating such therapeutic moieties to antibodies are well known and include, for example, those described in Amon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy" (Alan R. Liss, Inc. 1985) in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56; Hellstrom et al., "Antibodies For Drug Delivery" (Marcel Dekker, Inc. 1987) in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53; Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review" (1985) in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506; Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. See, for example, "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy" in Academic Press 1985, pp. 303-16, and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates," Immunol. Rev., 62:119-58 (1982).

[0030] Therapeutic agents suitable for use in the provided compositions and methods, for example, therapeutic agents for conjugation to the provided antibodies, include, but are not limited to, therapeutic agents selected from the group consisting of analgesics, anesthetics, stimulants, corticosteroids, anticholinergics, anticholinesterases, anticonvulsants, antitumor agents, allosteric inhibitors, anabolic steroids, antirheumatic agents, psychotherapeutic agents, neuroleptic agents, anti-inflammatory agents, anthelmintics, antibiotics, anticoagulants, antifungal agents, antihistamines, antimuscarinic agents, antimycobacterial agents, antiprotozoal agents, antiviral agents, dopaminergic agents, hematopoietic agents, immunological agents, muscarinic agents, protease inhibitors, vitamins, growth factors, and hormones. The choice of agent and dosage can be readily determined by one of skill in the art based on the given disease being treated.

[0031] As described herein, the antibody may be linked or conjugated to an imaging agent. Imaging agents and their uses are known. In some cases, the imaging agent is a "detectable moiety", which is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., those commonly used in ELISA), biotin, digoxigenin, or haptens, as well as proteins or other entities that can be made detectable, for example, by incorporating a radioactive label into a peptide or antibody that specifically reacts with a target peptide. Any method known in the art for conjugating an antibody to a label may be used, for example, using the methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc, San Diego. The detectable moiety may be selected from the group consisting of gamma emitters, beta emitters, and alpha emitters, gamma emitters, positron emitters, X-ray emitters, and fluorescent emitters. Suitable fluorescent compounds include sodium fluorescein, fluorescein isothiocyanate, phycoerythrin, Texas Red sulfonyl chloride, allophycocyanin (APC), Cy5-PE, CY7-APC, and Cascade Yellow.

[0032] In some cases, the detectable moiety may be visualized using histochemical techniques, ELISA-like assays, confocal microscopy, fluorescence detection, cell sorting, nuclear magnetic resonance, radioimmunoscintigraphy, X-ray imaging, positron emission tomography, computed axial tomography, magnetic resonance imaging, and ultrasound imaging.

[0033] A "label" or a "detectable moiety" is a composition that can be detected by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (such as those commonly used in ELISA), biotin, digoxigenin, or haptens, as well as proteins or other entities that can be made detectable, for example, by incorporating a radioactive label into a peptide or antibody that specifically reacts with a target peptide. Any method known in the art for conjugating an antibody to a label can be used, for example, using the methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc, San Diego.

[0034] The subject matter of the present disclosure provides a container that contains a pharmaceutical composition comprising an antibody provided in the present disclosure.Optionally, the antibody of the present disclosure can be administered to a subject with one or more additional agents, such as an antiviral agent, or an anticancer agent, or an analgesic agent.

[0035] The pharmaceutical composition may also include a pharmaceutically acceptable carrier or adjuvant for administering the antibody or antigen-binding protein. Optionally, the carrier is pharmaceutically acceptable for use in humans. The carrier or adjuvant should not itself induce the production of antibodies harmful to the individual receiving the composition, and should not be toxic. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles.

[0036] Pharmaceutically acceptable salts may be used, for example mineral acid salts such as hydrochlorides, hydrobromides, phosphates and sulfates, or organic acid salts such as acetates, propionates, malonates and benzoates.

[0037] The pharma- ceutically acceptable carrier in the therapeutic composition may additionally contain liquid such as water, saline, glycerol and ethanol.In addition, auxiliary substances such as wetting agents or emulsifiers or pH buffering substances may be present in such compositions.Such carriers allow the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions for ingestion by patients.

[0038] The compositions of the presently disclosed subject matter may further comprise a carrier to facilitate preparation and administration of the compositions. Microcapsules, such as microspheres or nanospheres (Manome et al. (1994) Cancer Res 54:5408-5413; Saltzman & Fung (1997) Adv Drug Deliv Rev 26:209-230), glycosaminoglycans (U.S. Pat. No. 6,106,866), fatty acids (U.S. Pat. No. 5,994,392), lipid emulsions (U.S. Pat. No. 5,651,991), lipids or lipid derivatives (U.S. Pat. No. 5,786,387), collagen (U.S. Pat. No. 5,922,356), polysaccharides or derivatives thereof (U.S. Pat. No. 5,688,931), nanosuspensions (U.S. Pat. No. 5,858,410), polymeric micelles or conjugates (Goldman et al. (1997) Cancer Res 26:209-230). 57:1447-1451, and U.S. Patent Nos. 4,551,482, 5,714,166, 5,510,103, 5,490,840, and 5,855,900), and polysomes (U.S. Patent No. 5,922,545).

[0039] The antibody sequences can be coupled to the active agent or carrier using methods known in the art, including, but not limited to, carbodiimide conjugation, esterification, sodium periodate oxidation followed by reductive alkylation, and glutaraldehyde cross-linking (Goldman et al. (1997) Cancer Res. 57:1447-1451; Cheng (1996) Hum. Gene Ther. 7:275-282; Neri et al. (1997) Nat. Biotechnol. 15:1271-1275; Nabel (1997) Vectors for Gene Therapy. In Current Protocols in Human Genetics, John Wiley & Sons, New York; Park et al. (1997) Adv. Pharmacol. 40:399-435; Pasqualini et al. ... al. (1997) Nat. Biotechnol. 15:542-546; Bauminger & Wilchek (1980) Meth. Enzymol. 70:151-159; U.S. Patent No. 6,071,890; and European Patent No. 0439095).

[0040] The therapeutic compositions of the present invention, in some embodiments, include pharmaceutical compositions that include a pharma- ceutically acceptable carrier. Suitable formulations include aqueous and non-aqueous sterile injection solutions that may include antioxidants, buffers, bacteriostatic agents, bactericidal antibiotics, and solutes that render the formulation isotonic with the body fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized) state that requires only the addition of a sterile liquid carrier, such as water for injection, immediately prior to use. Some exemplary components are SDS, in some embodiments in the range of 0.1 to 10 mg / ml, in some embodiments about 2.0 mg / ml; and / or mannitol or another sugar, in some embodiments in the range of 10 to 100 mg / ml, in some embodiments about 30 mg / ml; and / or phosphate buffered saline (PBS). Any other agents commonly used in the art may be used, taking into account the type of formulation in question. In some embodiments, the carrier is pharma- ceutically acceptable, hi some embodiments, the carrier is pharma- ceutically acceptable for use in humans.

[0041] The pharmaceutical compositions of the present disclosure may have a pH of 5.5 to 8.5, preferably 6 to 8, more preferably about 7. The pH may be maintained by the use of a buffer. The compositions may be sterile and / or pyrogen-free. The compositions may be isotonic to humans. The pharmaceutical compositions of the present disclosure may be supplied in a sealed container.

[0042] The pharmaceutical composition may comprise an effective amount of one or more antibodies described herein. In some embodiments, the pharmaceutical composition may comprise an amount sufficient to treat, ameliorate, or prevent the desired disease or condition, or to exhibit a detectable therapeutic effect. The therapeutic effect may also include a reduction in physical symptoms. The exact effective amount for a particular subject will vary depending on the subject's size and health, the nature and extent of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The effective amount for a given situation can be determined by routine experimentation performed by one of ordinary skill in the art.

[0043] The pharmaceutical composition of the present invention may be administered in various unit dosage forms depending on the method of administration. The dosage of a typical antibody pharmaceutical composition is well known to those skilled in the art. Such dosages are typically advisory and are adjusted according to the particular treatment situation or patient tolerance. The amount of antibody sufficient to achieve this is defined as a "therapeutically effective amount". The effective administration schedule and amount for this use, i.e., "administration regimen", will depend on various factors, including the stage of the disease or condition, the severity of the disease or condition, the general health of the patient, the physical condition of the patient, age, the pharmaceutical formulation and concentration of the active agent, and the like. The mode of administration is also taken into consideration when calculating the administration regimen for a patient. The administration regimen should also take into account the pharmacokinetics, i.e., the absorption rate, bioavailability, metabolism, clearance, and the like, of the pharmaceutical composition. See, for example, Remington's latest; Egleton, Peptides 18:1431-1439, 1997; Langer, Science 249:1527-1533, 1990.

[0044] Also provided herein is a method for treating a vimentin-expressing cancer in a subject, comprising administering to the subject an antibody from a container, e.g., a bottle or vial, provided herein, thereby treating the vimentin-expressing cancer in the subject. Optionally, the container is a glass or PETG container. Optionally, the cancer is a brain tumor and a pancreatic cancer. Optionally, the brain tumor is a glioblastoma. Optionally, the subject is administered a therapeutically effective amount of the composition.

[0045] For purposes of the present invention, a therapeutically effective amount of a composition comprising an antibody comprises about 0.05 to 1500 μg of protein, preferably about 10 to 1000 μg of protein, more preferably about 30 to 500 μg, and most preferably about 40 to 300 pg, or any integer between these values. For example, an antibody of the present invention may be administered to a subject at a dose of about 0.1 μg to about 200 mg, e.g., about 0.1 μg to about 5 μg, about 5 μg to about 10 μg, about 10 μg to about 25 μg, about 25 μg to about 50 μg, about 50 μg to about 100 μg, about 100 μg to about 500 μg, about 500 μg to about 1 mg, about 1 mg to about 2 mg, optionally with a booster administered, e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 6 months, and / or 1 year later. It will be understood that the specific dosage level for a particular patient will depend on a variety of factors, including the activity of the antibody used, age, body weight, general health, sex, diet, time of administration, route of administration and rate of excretion, drug combination, and the severity of the particular disease being treated.

[0046] Routes of administration include, but are not limited to, oral, topical, subcutaneous, intramuscular, intravenous, subcutaneous, intradermal, transdermal and subcutaneous. Depending on the route of administration, the volume per dose is preferably about 0.001 to 10 ml, more preferably about 0.01 to 5 ml, and most preferably about 0.1 to 3 ml. The composition may be administered in a single dose treatment or multiple dose treatments over a period of time, on a schedule suitable for the age, weight and condition of the subject, the particular antibody formulation used, and the route of administration.

[0047] Also provided herein is a kit that includes a container containing the antibody and instructions for use. Optionally, the container has a label. Suitable containers include, for example, bottles, vials, and test tubes. The container is made of glass or PETG. The container holds a composition that includes the antibody provided herein, which is effective for therapeutic use. The label on the container indicates that the composition is used for a specific therapeutic or non-therapeutic use, and can also indicate instructions for use either in vivo or in vitro.

[0048] The following examples of specific embodiments for carrying out the present invention are offered for illustrative purposes only and are not intended to limit the scope of the invention in any way. EXAMPLES

[0049] Example 1. Storage containers and conditions affect antibody activity To determine whether the commercially available storage vials containing the antibody pritumumab affect the potency of the antibody, binding assays were performed on three different antibody lots. The first drug substance (DS) antibody lot was housed at a concentration of 10 mg / ml (approximately 4.5 ml volume) in (i) Wheaton (#223739) clear glass serum bottles (10 ml size) with a 20 mm crimp top finish (low-alkali borosilicate molded glass) or at a concentration of 10 mg / ml (approximately 4 ml volume) in (ii) clear PETG serum vials (#1-0456-81P; ThermoFisher Scientific) with liners and screw caps (5 ml size). The second DS antibody lot was housed at a concentration of 9.9 mg / ml (1 ml volume) in Nalgene cryogenic storage vials (#5000-1020) (1.5 ml size polypropylene (PP) screw top vials). The third antibody lot and reference standard for potency assays is at a concentration of 9.72 mg / ml (4 ml volume) in liner-equipped screw-cap PETG serum vials (#1-0456-81P; ThermoFisher Scientific) (5 ml size; polyethylene terephthalate G (PETG)).

[0050] The potency of the second antibody lot stored in a PP cryovial was compared to the first antibody lot stored in a clear PETG serum vial. The results in Figure 1 show a significant difference in the potency of drug substance (DS) stored in a PP cryovial and a PETG serum vial. The EC50 of the clinical DS in a PETG vial was 9.6ug / ml, whereas the EC50 in a PP cryovial was 20ug / ml. The potency of the DS clinical lot stored in a PETG serum vial (9.6ug / ml) was similar to that of the DS clinical lot stored in a glass serum vial (8.25ug / ml). This result suggests that the difference in EC50 values ​​between the clinical drug substance and the clinical drug product is a result of storage in different containers. The clinical DS lot stored in a PP cryovial showed weak potency and may not correspond to the potency of the drug substance stored in a glass serum vial.

[0051] Binding assays were performed to compare the 3rd antibody DS lots and reference standards stored in PP cryovials with those stored in PETG serum vials. ELISA binding assays were performed on three separate 3rd antibody DS lots in PP cryovials and one 3rd antibody DS lot in PETG serum vials. The results in Figure 2 show that the DS lots stored in PP cryovials do not exhibit the same potency as those stored in PETG serum vials. The PP cryovial stored DS lots showed significantly lower binding (EC50 ranging from 37ug / ml to 40ug / ml) compared to the DS lot in PETG serum vials (EC50 11ug / ml).

[0052] Binding ELISA assays compared clinical lots of DS stored in PP cryovials with clinical lots of DS stored in PETG serum vials. There were significant potency differences between these samples. EC50 values ​​for DS stored in PETG serum vials were similar to those reported for clinical DS lots stored in glass containers and for the lot DS reference standard used in previous binding assays. Neither clinical DS stored in PP cryovials nor reference standard DS stored in PP cryovials matched the formulation (stored in glass serum vials) in potency. However, both clinical DS and toxicological DS stored in PETG serum vials showed EC50 values ​​similar to the formulation material and matched the formulation in potency.

[0053] In addition to the container used to store the antibody, the storage conditions and formulation of the antibody were also tested. Storage of the product at 5°C was found to result in degradation of the antibody. Storage at temperatures below -60°C for three freeze-thaw cycles did not result in degradation. It is recommended / documented that this antibody be stored below -60°C for long term storage. Additionally, the preferred concentration and formulation of the antibody in the clinical product vial was determined to be approximately 10 mg / ml in 10 mM sodium phosphate, 150 mM sodium chloride pH 7.0 (phosphate buffered saline (PBS)).

[0054] Example 2. Pritumumab specifically binds to the cell surface of glioma cells and shows specificity for vimentin. To determine whether pritumumab binds to the surface of glioma cells, we performed an assay to determine whether pritumumab can compete with and displace recombinant human vimentin. The rationale for this experiment was to further demonstrate the specificity of the pritumumab antibody for extracellular vimentin.

[0055] Figures 1 and 2 show the results of flow cytometry experiments. Table 1 summarizes the binding competition experiments. Incubation of 160 nM pritumumab with 45 nM recombinant vimentin does not result in superior binding to U251 cells. However, incubation of 160 nM pritumumab with a 2.5 molar excess of recombinant vimentin (450 nM) can block pritumumab binding to the U251 cell surface.

[0056] [Table 1]

[0057] The conclusion is that recombinant vimentin can compete with pritumumab for binding to the cell surface of glioma cells, further demonstrating the specificity of pritumumab binding to vimentin.

[0058] To determine the binding affinity of the antibody pritumumab to vimentin, binding of the antibody to human vimentin was measured using an Octet HTX. Binding experiments were performed on an Octet HTX at 25°C. Pritumumab (10ug / ml) was loaded onto an anti-human Fc (AHC) biosensor. The loaded sensor was bathed in a series of antigen dilutions (recombinant human vimentin) (starting at 300nM, 1:3 descending, 7 points). Kinetic constants were calculated using a monovalent (1:1) model. The binding affinity of the antibody pritumumab to vimentin was determined to be 7.55E-9M.

[0059] [Table 2]

[0060] Example 3. Immunohistochemical staining of CNS tissues The purpose of this example was to determine whether the human monoclonal antibody, pritumumab, stains central nervous system (CNS) neoplasms, specifically glioblastomas and astrocytomas, which are the most common and aggressive primary CNS malignancies. To this end, immunohistochemical staining was performed on 80 human tissue cores; 70 cores were from patients with glioblastoma and astrocytoma, and 10 from normal brain.

[0061] Glass slides containing unstained TMA cores of normal human and monkey subjects were obtained. Paraffin section slides were cut from tissue blocks and dried overnight in a 60 degree oven. Slides were deparaffinized using heat-induced epitope retrieval technique with Dako Target Retrieval Solution, ph 9.0 EDTA (Dako cat #S2367) by pressure cooking for 30 minutes. Slides were then exposed to 3% H2O2 for 10 minutes in a DAKO Autostainer (model #S3800) and exposed to primary pritumumab antibody diluted 1:10 for 2 hours at room temperature. Slides were then exposed to polymer-horseradish peroxidase anti-human IgG / rabbit antibody for 30 minutes, after which slides were exposed to DAB for 10 minutes and counterstained with hematoxylin for 1 minute before being dehydrated and coverslipped. TMA cores were scanned on an Aperio ST Turbo scanner and links to images were made available for histomorphometric examination and scoring. The display software is proprietary to HistoWiz.

[0062] The TMA cores were from human brain (CNS) tissue and consisted of examples of glioblastoma, astrocytoma, and normal cerebrum. All human glioblastoma TMA cores show either nuclear or cytoplasmic positivity. There was variability in the intensity of staining, but this was not related to the grade or type of glioblastoma. Rare examples showed strong cytoplasmic staining (see Figures 5A and 5B). All glioblastomas with a large round cytoplasmic pattern showed moderate cytoplasmic staining. Low grade astrocytomas also demonstrated nuclear staining. Normal brain cores show astroglial staining. Neurons show some granular cytoplasmic staining. See Figures 6A and 6B.

[0063] In summary, pritumumab was positive in all astrocytomas and glioblastomas. The intensity of staining varied from case to case. The predominant localization was nuclear. Cytoplasmic staining was usually weak or absent, although one case showed strong cytoplasmic staining.

Claims

1. A glass or polyethylene terephthalate G (PETG) vial containing an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:

2.

2. 2. The vial of claim 1, wherein the vial is a glass vial.

3. 2. The vial of claim 1, wherein the vial is a PETG vial.

4. The vial according to any one of claims 1 to 5, wherein the antibody has an isoelectric point of 8.0 to 9.

0.

5. 5. The vial of claim 4, wherein the antibody has an isoelectric point of about 8.

7.

6. The vial according to any one of claims 1 to 5, wherein the antibody is capable of crossing the blood-brain barrier.

7. The vial according to any one of claims 1 to 6, wherein the antibody binds to vimentin.

8. The vial of claim 7 , wherein vimentin is located on the surface of a cancer cell.

9. The vial of claim 7 , wherein the vimentin is secreted by cancer cells.

10. 10. The vial of claim 8 or 9, wherein the cancer is selected from the group consisting of brain cancer and pancreatic cancer.

11. The vial of any one of claims 1 to 10, wherein the vial contains 5 mg / ml to 15 mg / ml of the antibody.

12. The vial of any one of claims 1 to 11, wherein the antibody is conjugated to a drug.

13. 13. The vial of claim 12, wherein the agent is a therapeutic or diagnostic agent.

14. 14. The vial of claim 13, wherein the therapeutic agent is a chemotherapeutic agent.

15. 14. The vial of claim 13, wherein the diagnostic agent is a fluorescent agent, a radioactive agent, or a chemiluminescent agent.

16. The vial of any one of claims 1 to 15, wherein the vial can be stored for an extended period of time.

17. The vial of any one of claims 1 to 16, wherein the antibody retains its activity over three freeze / thaw cycles.

18. The vial of any one of claims 1 to 17, wherein the antibody can be stored at a temperature below -60°C.

19. A kit comprising a vial according to any one of claims 1 to 18 and instructions for use.

20. 20. A method of delivering an antibody across the blood-brain barrier, comprising administering to a subject an antibody from a vial of any one of claims 1 to 18, thereby delivering the antibody across the blood-brain barrier.

21. A method of treating a cancer that expresses vimentin in a subject, comprising administering to the subject an antibody from a vial according to any one of claims 1 to 18, thereby treating the cancer that expresses vimentin in the subject.

Citation Information

Patent Citations

  • Antibody preparations

    JP2008520551A

  • Anti-pdl1 antibody formulation

    JP2016533335A

  • protein preparation

    JP2017519777A

  • Methods for Improved Drug Delivery to the Brain

    JP2018531625A